Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: A novel mechanism for vascular protection in chronic systemic inflammation

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 439-448

  Thornton, C C ^a   Al Rashed, F ^a,b   Calay, D ^a   Birdsey, G M ^a   Bauer, A ^a   Mylroie, H ^a   Morley, B J ^c   Randi, A M ^a   Haskard, D O ^a   Boyle, J J ^a   Mason, J C ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^c UNIVERSITY OF BATH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSE; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERCELLULAR ADHESION MOLECULE 1; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; DEAMINASE; INOSINE MONOPHOSPHATE SYNTHASE; MULTIENZYME COMPLEX; SUPEROXIDE DISMUTASE; TRANSFERASE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FEMALE; GENE; HEART PROTECTION; HO1 GENE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MNSOD GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR ENDOTHELIUM; ANIMAL; DRUG EFFECTS; INFLAMMATION; METABOLISM; PHOSPHORYLATION; RHEUMATOID VASCULITIS; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIRHEUMATIC AGENTS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENDOTHELIUM, VASCULAR; HEME OXYGENASE-1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; INFLAMMATION; METHOTREXATE; MICE; MULTIENZYME COMPLEXES; NUCLEOTIDE DEAMINASES; PHOSPHORYLATION; RHEUMATOID VASCULITIS; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954401987     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206305     Document Type: Article

References (44)

1. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100:328-41.
2. Morrow VA, Foufelle F, Connell JM, et al. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003;278:31629-39.
3. Kukidome D, Nishikawa T, Sonoda K, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006;55:120-7.
4. Liu C, Liang B, Wang Q, et al. Activation of AMP-activated protein kinase α1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin. J Biol Chem 2010;285:15346-55.
5. Wang S, Zhang M, Liang B, et al. AMPK α2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 2010;106:1117-28.
6. Schulz E, Dopheide J, Schuhmacher S, et al. Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation 2008;118:1347-57.
7. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70.
8. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
9. Guin A, Chatterjee Adhikari M, Chakraborty S, et al. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 2013;43:48-54.
10. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207 e15.
11. Chan ES, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol 2010;6:175-8.
12. Cronstein BN, Eberle MA, Gruber HE, et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991;88:2441-5.
13. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
14. Hang LM, Izui S, Dixon FJ. (NZW×BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981;154:216-21.
15. Hashimoto Y, Kawamura M, Ichikawa K, et al. Anticardiolipin antibodies in NZW×BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992;149:1063-8.
16. Berden JH, Hang L, McConahey PJ, et al. Analysis of vascular lesions in murine SLE. I. Association with serologic abnormalities. J Immunol 1983;130:1699-705.
17. Accinni L, Dixon FJ. Degenerative vascular disease and myocardial infarction in mice with lupus-like syndrome. Am J Pathol 1979;96:477-92.
18. Al-Abd AM, Inglis JJ, Nofal SM, et al. Nimesulide improves the disease modifying anti-rheumatic profile of methotrexate in mice with collagen-induced arthritis. Eur J Pharmacol 2010;644:245-50.
19. Yoshida H, Fujiwara H, Fujiwara T, et al. Quantitative analysis of myocardial infarction in (NZW×BXSB)F1 hybrid mice with systemic lupus erythematosus and small coronary artery disease. Am J Pathol 1987;129:477-85.
20. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009;105:114-27.
21. Ballinger SW, Patterson C, Knight-Lozano CA, et al. Mitochondrial integrity and function in atherogenesis. Circulation 2002;106:544-9.
22. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheum 1995;34:421-8.
23. Colombo SL, Moncada S. AMPKα1 regulates the antioxidant status of vascular endothelial cells. Biochem J 2009;421:163-9.
24. Thomson DM, Herway ST, Fillmore N, et al. AMP-activated protein kinase phosphorylates transcription factors of the CREB family. J Appl Physiol 2008;104:429-38.
25. Schauer IE, Knaub LA, Lloyd M, et al. CREB downregulation in vascular disease: a common response to cardiovascular risk. Arterioscler Thromb Vasc Biol 2010;30:733-41.
26. Kim HP, Roe JH, Chock PB, et al. Transcriptional activation of the human manganese superoxide dismutase gene mediated by tetradecanoylphorbol acetate. J Biol Chem 1999;274:37455-60.
27. Anderson CA, Jee SH, Charleston J, et al. Effects of folic acid supplementation on serum folate and plasma homocysteine concentrations in older adults: a dose-response trial. Am J Epidemiol 2010;172:932-41.
28. Landewe RB, van den Borne BE, Breedveld FC, et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000;355:1616-17.
29. Bulgarelli A, Martins Dias AA, Caramelli B, et al. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2012;59:308-14.
30. Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008;58:3675-83.
31. Recio-Mayoral A, Mason JC, Kaski JC, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009;30:1837-43.
32. Mihara M, Katsume A, Takeda Y. Effect of methotrexate treatment on the onset of autoimmune kidney disease in lupus mice. Chem Pharm Bull (Tokyo) 1992;40: 2177-81.
33. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013;493:346-55.
34. Alrashed F, Calay D, Thornton C, et al. Celecoxib-mediated activation of an AMPK-CREB-Nrf2 dependent pathway: a novel mechanism for endothelial cytoprotection in chronic systemic inflammation. Cardiovasc Res 2014;103:S31-2.
35. Beckers A, Organe S, Timmermans L, et al. Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther 2006;5:2211-17.
36. Pirkmajer S, Kulkarni SS, Tom RZ, et al. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. Diabetes 2014 (Epub ahead of print 22 Oct 2014).
37. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the α2 isoform. Biochem J 1998;334(Pt 1):177-87.
38. Watson PA, Birdsey N, Huggins GS, et al. Cardiac-specific overexpression of dominant-negative CREB leads to increased mortality and mitochondrial dysfunction in female mice. Am J Physiol Heart Circ Physiol 2010;299:H2056-68.
39. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609.
40. Conkright MD, Guzman E, Flechner L, et al. Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Mol Cell 2003;11:1101-8.
41. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Fr Rad Biol Med 2009;47:344-56.
42. Liu XM, Peyton KJ, Shebib AR, et al. Compound C stimulates heme oxygenase-1 gene expression via the Nrf2-ARE pathway to preserve human endothelial cell survival. Biochem Pharm 2011;82:371-9.
43. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996;270:C522-9.
44. Riksen NP, Barrera P, van den Broek PH, et al. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70.